1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Germany >
  5. OpGen Acquires Curetis N.V.

M&A Deal Summary

OpGen Acquires Curetis N.V.

On September 4, 2019, OpGen acquired medical products company Curetis N.V.

Acquisition Highlights
  • This is OpGen’s 2nd transaction in the Medical Products sector.
  • This is OpGen’s 1st transaction in Germany.

M&A Deal Summary
Date 2019-09-04
Target Curetis N.V.
Sector Medical Products
Buyer(s) OpGen
Deal Type Add-on Acquisition

Target

Curetis N.V.

Holzgerlingen, Germany
Curetis is a molecular diagnostics company that focuses on the development and commercialization of reliable, fast and cost-effective syndromic testing products for the diagnosis of severe infectious diseases. The diagnostic solution Unyvero of Curetis enables rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques. Curetis was formed in 2007 and is based in Holzgerlingen, Germany.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

OpGen

Rockville, Maryland, United States
Category Company
Founded 2001
Sector Life Science
Employees38
Revenue 3M USD (2024)
DESCRIPTION

OpGen is an early commercial-stage company using molecular testing and bioinformatics to assist healthcare providers in combating multi-drug-resistant bacterial infections. OpGen was founded in 2001 and is based in Rockville, Maryland.

DEAL STATS #
Overall 2 of 2
Sector: Medical Products M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
Country: Germany M&A 1 of 1
Year: 2019 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-14 AdvanDx

Woburn, Massachusetts, United States

AdvanDx, Inc. is a developer of advanced molecular diagnostic products for the diagnosis and treatment of life-threatening infections.

Buy -
Mergr

Solution for

Product

Company

Legal